These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34447697)

  • 1. Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma.
    Aili A; Wen J; Xue L; Wang J
    Front Oncol; 2021; 11():712765. PubMed ID: 34447697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
    Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
    Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
    Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
    Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.
    He D; Ma T; Yi N; Zhang S; Ding G
    Biotechnol Genet Eng Rev; 2023 Apr; ():1-15. PubMed ID: 37079762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
    Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
    Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
    Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analyses of
    Yang Q; Shen R; Xu H; Shi X; Xu L; Zhang L; Fan X; Jin X
    Ann Transl Med; 2021 Mar; 9(6):465. PubMed ID: 33850862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.
    Murakami A; Wang L; Kalhorn S; Schraml P; Rathmell WK; Tan AC; Nemenoff R; Stenmark K; Jiang BH; Reyland ME; Heasley L; Hu CJ
    Oncogenesis; 2017 Jan; 6(1):e287. PubMed ID: 28092369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
    Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
    Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
    Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
    Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients.
    Huang J; Cai W; Cai B; Kong W; Zhai W; Zhang J; Chen Y; Chen S; Bai Y; Huang Y; Xue W
    Front Oncol; 2021; 11():697219. PubMed ID: 34568025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.
    Fultang N; Schwab AM; McAneny-Droz S; Grego A; Rodgers S; Torres BV; Heiser D; Scherle P; Bhagwat N
    Front Oncol; 2024; 14():1343004. PubMed ID: 38371625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting prognosis and immunotherapeutic response of clear cell renal cell carcinoma.
    Wang J; Tu W; Qiu J; Wang D
    Front Pharmacol; 2022; 13():984080. PubMed ID: 36313281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring a ferroptosis and oxidative stress-based prognostic model for clear cell renal cell carcinoma.
    Lin D; Hu B; Zhu S; Wu Y
    Front Oncol; 2023; 13():1131473. PubMed ID: 37064095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.